The authors describe an HIV-infected patient with moderate renal failure receiving combination antiretroviral therapy. Because of dyslipidaemia he was initially treated with pravastatin but developed rhabdomyolysis after a switch to rosuvastatin. With this case we illustrate that statins as well as antiretroviral therapy are susceptible to clinical relevant drug–drug or drug–disease interactions. Knowledge of these interactions is important to provide patients with the best possible care.
References
1.
AbergJ.A.Cardiovascular complications in HIV management: past, present and future. J Acquir Immune Defic Syndr2009; 50: 54–64.
2.
BurgerD., StroesE., ReissP.Drug interactions between statins and antiretroviral agents. Curr Opin HIV AIDS2008; 3: 247–251.
3.
DubéM.P., SteinJ.H., AbergJ.A.Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis2003; 37: 613–627.
4.
European AIDS Clinical Society.Guidelines: clinical management and treatment of HIV infected adults in Europe. Version 5, 2009. (Updated 27 July 2010. Accessed 14 September 2010.) Available from http://www.europeanaidsclinicalsociety.org/guidelines.asp.
5.
WilliamsD., FeelyJ.Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet2002; 41: 343–370.
6.
AarnoutseR.E., BurgerD.M.When should we fear statin interactions? In VissersM.N. (Editor). Evidence-based management of lipid disorders. 1st Ed.Castle Hill Barn, UK: Tfm Publishing Ltd2010; pp. 267–283.
van der LeeM., SankatsingR., SchippersE.Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther2007; 12: 1127–1132.
9.
KiserJ.J., GerberJ.G., PredhommeJ.A., WolfeP., FlynnD.M., HoodyD.W.Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr2008; 47: 570–578.
10.
Crestor (rosuvastatin calcium).Package insert2009. AstraZeneca PharmaceuticalsWilmington, DE, USA.
11.
NaranjoC.A., BustoU., SellersE.M.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
12.
Cipro (ciprofloxacin hydrochloride).Package insert2008. Schering CorporationKenilworth, NJ, USA.
13.
EiseleS., GarbeE., ZeitzM., SchneiderT., SomasundaramR.Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment: a case report and review of the literature. Int J Clin Pharmacol Ther2009; 47: 165–168.
14.
SawantR.D.Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. Can J Clin Pharmacol2009; 16: e78–e79.